"Cytarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
| Descriptor ID |
D003561
|
| MeSH Number(s) |
D03.383.742.680.245.453 D13.570.065.300 D13.570.685.245.453
|
| Concept/Terms |
Cytarabine- Cytarabine
- Arabinofuranosylcytosine
- Aracytidine
- Cytosine Arabinoside
- Arabinoside, Cytosine
- Arabinosylcytosine
Cytosar- Cytosar
- Cytosar-U
- Cytosar U
- CytosarU
|
Below are MeSH descriptors whose meaning is more general than "Cytarabine".
Below are MeSH descriptors whose meaning is more specific than "Cytarabine".
This graph shows the total number of publications written about "Cytarabine" by people in this website by year, and whether "Cytarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 3 | 4 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 3 | 3 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytarabine" by people in Profiles.
-
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Am J Hematol. 2025 Mar; 100(3):402-407.
-
FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy. J Cell Mol Med. 2025 Jan; 29(1):e70169.
-
Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025 Jan-Feb; 75(1):46-67.
-
Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience. Ann Hematol. 2024 Dec; 103(12):5395-5403.
-
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024 Oct 01; 130(19):3333-3343.
-
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 2024 04 23; 8(8):2020-2029.
-
Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol. 2024 05; 99(5):890-899.
-
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. Br J Haematol. 2024 Mar; 204(3):898-909.
-
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
-
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatr Blood Cancer. 2023 Dec; 70(12):e30672.